<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608540</url>
  </required_header>
  <id_info>
    <org_study_id>P2018/263</org_study_id>
    <nct_id>NCT03608540</nct_id>
  </id_info>
  <brief_title>Endomina as an Aid for Endoscopic Full Thickness Resection</brief_title>
  <acronym>EFTR</acronym>
  <official_title>A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Full Thickness Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concept of natural orifice transluminal endoscopic surgery (NOTES) (1) has evolved to&#xD;
      endoscopic full thickness resection (EFTR). It represents innovation in technique that allows&#xD;
      endoscopists to advance further into the endoscopic surgical space. EFTR has transformed the&#xD;
      ability to tackle subepithelial tumors (SETs) and early mucosal neoplasm that are not&#xD;
      amenable to classic ESD technique, enhance the staging accuracies for marginal lesions, and&#xD;
      even increase the diagnostic capabilities for infiltrative disorders. Thus far, multiple&#xD;
      methods have been described to perform EFTR, including nonexposed and exposed techniques,&#xD;
      with the closure occuring before resection or after resection, respectively (2). Early&#xD;
      comparative studies show no difference between the two methods (3). However, the procedures&#xD;
      themselves are limited by the current tools available and by described techniques to achieve&#xD;
      resection.&#xD;
&#xD;
      Investigators are described here a novel non-exposed technique, with closure before&#xD;
      resection, using the Endomina device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all Adverse Device Effects</measure>
    <time_frame>one year from procedure</time_frame>
    <description>Safety will be characterized by the incidence of all Adverse Device Effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection</measure>
    <time_frame>1 month after resection</time_frame>
    <description>R0 resection at histology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Submucosal Tumor of Intestine</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suturing system with suture apposition then bulging formation then cutting the lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endomina</intervention_name>
    <description>Suturing system with sutures apposition then bulging then cutting</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Lesion untreatable with standard technique.&#xD;
&#xD;
          2. Age between 18-65 years;&#xD;
&#xD;
          3. Must be able to comply with all study requirements for the duration of the study as&#xD;
             outlined in the protocol. This includes complying with the visit schedule as well as&#xD;
             study specific procedures such as: clinical assessment, endoscopy, radiography, as&#xD;
             well as laboratory investigations;&#xD;
&#xD;
          4. Must be able to understand and be willing to provide written informed consent;&#xD;
&#xD;
          5. Must live within 75 km of the treatment site;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Achalasia and any other esophageal motility disorders (for upper GI lesion)&#xD;
&#xD;
          2. Severe esophagitis (for upper GI lesion)&#xD;
&#xD;
          3. Gastro-duodenal ulcer (for upper GI lesion)&#xD;
&#xD;
          4. Severe renal, hepatic, pulmonary disease or cancer;&#xD;
&#xD;
          5. GI stenosis or obstruction;&#xD;
&#xD;
          6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;&#xD;
&#xD;
          7. Anticoagulant therapy;&#xD;
&#xD;
          8. Impending gastric surgery 60 days post intervention (Upper GI);&#xD;
&#xD;
          9. Currently participating in other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastroenterology Department Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Huberty, MD</last_name>
      <phone>+3225553715</phone>
      <email>vincent.huberty@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

